Does UnitedHealthcare Cover Metformin?

How UnitedHealthcare Formularies Are Organized

UnitedHealthcare uses a tiered drug formulary system that places medicines into categories based on cost and clinical preference. Generic drugs sit at Tier 1 or Tier 2, preferred brand-name drugs at Tier 3, non-preferred brands at Tier 4, and specialty drugs at Tier 5. Metformin hydrochloride, the generic form, lands at Tier 1 on the large majority of UHC commercial plans, Medicare Advantage Part D plans, and UHC Medicaid managed-care contracts.

Understanding tier placement matters because it directly sets your copay or coinsurance at the pharmacy counter. Tier 1 generics on UHC commercial plans typically carry a $0 to $15 copay per 30-day fill when you use an in-network pharmacy. Some high-deductible health plans (HDHPs) require you to meet your deductible first, after which the Tier 1 copay applies. Medicare Advantage Part D plans under UHC often list metformin in the "Preferred Generic" cost-sharing level, where 2025 copays on many plans are $0 to $5 for a 90-day supply through mail-order.

The FDA approved metformin for type 2 diabetes management in 1994, and decades of post-marketing data confirm its safety profile [1]. Generic availability since the early 2000s pushed its price below $10 per month at major retail pharmacies without insurance, which is part of why insurers consistently place it at Tier 1. The American Diabetes Association's 2024 Standards of Care in Diabetes list metformin as a first-line pharmacologic agent for type 2 diabetes [2], and formulary committees follow that recommendation when assigning tier status.

UHC publishes its formulary lists publicly at uhcprovider.com and myuhc.com. You can search by drug name, your plan name, and your state to verify the exact tier before filling a prescription. Formularies can change on January 1 of each plan year, so confirming coverage each January is good practice.

Which UnitedHealthcare Plans Cover Metformin?

Metformin appears on virtually every UHC plan type, though the cost-sharing details differ. Commercial employer-sponsored plans, individual marketplace plans, Medicare Advantage, dual-eligible special needs plans (D-SNPs), and UHC Medicaid contracts all list generic metformin at Tier 1. The main exception is certain very-high-deductible catastrophic plans, where you pay the full negotiated generic price until your deductible is met.

UHC Commercial (Employer and Individual): Most group and individual plans place generic metformin immediate-release (500 mg, 850 mg, 1 to 000 mg tablets) at Tier 1 with a $5 to $15 copay per 30-day supply. Extended-release generics are also typically Tier 1. Brand-name Glucophage or Glucophage XR may land at Tier 3 or Tier 4, adding $40 to $80 per fill.

UHC Medicare Advantage Part D: Under the Centers for Medicare and Medicaid Services (CMS) 2024 guidelines, Medicare Part D plans must cover insulin and certain other diabetes drugs at specific cost-sharing caps [3]. Metformin is not insulin, but CMS data from 2023 show it remains one of the most consistently covered generic drugs across all Part D sponsors. UHC Medicare Advantage formularies list generic metformin at $0 to $10 for a 30-day supply.

UHC Medicaid: UHC administers Medicaid managed care in more than 30 states. State Medicaid programs are required by federal law to cover metformin as a preferred drug for type 2 diabetes. Member cost-sharing for Medicaid is minimal, often $0 to $3 per prescription under federal cost-sharing limits [4].

UHC Community Plan (Dual Eligible/D-SNP): Members enrolled in dual-eligible plans pay $0 copays for most Tier 1 generics, including metformin, because both Medicare and Medicaid cost-sharing rules apply.

Prior Authorization and Step Therapy Rules

Generic metformin immediate-release does not require prior authorization (PA) on the overwhelming majority of UHC formularies. It is a first-line, guideline-concordant therapy, and PA requirements are typically reserved for expensive brand-name or specialty medications [5].

Extended-release generic metformin (metformin ER, also sold as Fortamet or Glumetza in brand form) also avoids PA on most UHC plans when dispensed as the generic. If your prescriber specifically writes for brand-name Glumetza or Fortamet, the plan may apply a PA or step-therapy requirement asking that you try the generic first.

Step therapy for metformin is uncommon. Step therapy rules generally require a patient to fail a less-expensive drug before the insurer covers a more expensive one. Because metformin itself is the least-expensive first-line option for type 2 diabetes, it is rarely the "step" a patient must take; it is the starting point [6].

If a PA is ever triggered (for example, if a prescriber codes the indication incorrectly or requests a brand-name product), your physician's office can submit clinical notes showing a confirmed type 2 diabetes diagnosis. Approval in that scenario is routine. The PA process under UHC typically takes 24 to 72 hours for standard review or up to 4 hours for urgent requests.

The Clinical Case for Metformin: Why Insurers and Guidelines Back It

Metformin's formulary placement reflects a deep evidence base. The UK Prospective Diabetes Study (UKPDS 34, N=1,704) demonstrated that metformin reduced all-cause mortality by 36% and diabetes-related endpoints by 32% compared with conventional diet therapy in overweight patients with type 2 diabetes [7]. That trial, published in 1998, remains one of the most cited datasets in endocrinology and directly informs why guidelines treat metformin as the default first-line agent.

The Diabetes Prevention Program (DPP, N=3,234) showed that metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31% over 2.8 years, compared with placebo [8]. A 15-year follow-up analysis of DPP participants (DPPOS) published in The Lancet Diabetes and Endocrinology found that metformin reduced diabetes incidence by 18% even in the long-term extension, with participants who had been randomized to metformin showing lasting benefit years after the controlled trial ended.

The ADA's 2024 Standards of Care state: "Metformin is recommended as the initial pharmacologic treatment for most patients with type 2 diabetes" [2]. The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Diabetes Management Algorithm similarly places metformin at the top of its pharmacotherapy decision tree for patients without specific comorbidity-driven indications for GLP-1 receptor agonists or SGLT-2 inhibitors [9].

Metformin works primarily by suppressing hepatic glucose production through AMP-activated protein kinase (AMPK) activation, with secondary effects on intestinal glucose absorption and peripheral insulin sensitivity [10]. Its weight-neutral to modest weight-reducing profile (average 1 to 3 kg loss in clinical trials) makes it favorable compared with sulfonylureas, which frequently cause weight gain.

Beyond glycemic control, metformin has attracted research interest for its possible effects on aging biology. The Targeting Aging with Metformin (TAME) trial, a large randomized controlled trial funded by the American Federation for Aging Research, is currently testing whether metformin delays the onset of age-related diseases in non-diabetic adults. Results are anticipated in 2025 and 2026. No regulatory body has approved metformin for longevity or anti-aging indications as of early 2025, so UHC and other insurers would not cover it for those off-label uses without a concurrent approved diagnosis [11].

What Metformin Costs Without UnitedHealthcare Coverage

Even without insurance, metformin is among the most affordable prescription drugs in the country. The cash price at major chains varies:

Walmart's $4 generic list covers metformin immediate-release up to a 30-day supply at many store locations. Costco Pharmacy lists metformin 500 mg, 60 tablets at roughly $4 to $6 without a membership required for pharmacy services in most states. CVS and Walgreens charge $10 to $25 per 30-day supply without a discount card.

GoodRx coupons can reduce the price to $4 to $10 at most major retail pharmacies. GoodRx Gold membership (approximately $10 per month per household) drops metformin prices further, often to $3 to $5 per fill.

The federally qualified health center (FQHC) network and 340B drug pricing program can also provide metformin at reduced cost for eligible low-income patients, independent of insurance status.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists metformin 500 mg (60 tablets) at approximately $5.40 including pharmacy dispensing fees, representing one of the lowest transparent cash prices available nationally.

How to Verify Your Specific UHC Plan's Metformin Coverage

Coverage details vary by plan ID, not just by insurer name. Three reliable methods exist for checking your exact benefit:

Method 1: myuhc.com formulary search. Log in with your member ID, manage to "Prescription Drug Coverage," and search "metformin." The tool returns the tier, copay, and any utilization management requirements for your specific plan.

Method 2: Call member services. The member services number is printed on the back of your UHC insurance card. Ask the representative for the formulary tier and copay for NDC (National Drug Code) 00093-1048-01 (a common generic metformin 500 mg code) or the specific NDC on your prescription bottle.

Method 3: Ask your pharmacy. Your pharmacist can run a benefits check using your insurance card before dispensing. This "test claim" shows the exact price your plan will charge before you commit to filling.

If your plan's deductible has not been met, you will pay the negotiated generic price rather than a fixed copay. In 2025, the average negotiated price for generic metformin at UHC in-network pharmacies is typically $8 to $18 per 30-day supply, well below most plan deductibles' pain threshold for a single generic medication.

Extended-Release vs. Immediate-Release: Does Coverage Differ?

Generic metformin extended-release (ER) and immediate-release (IR) are both covered at Tier 1 on most UHC plans. The brand-name extended-release products, Glucophage XR, Fortamet, and Glumetza, may be placed at Tier 3 or higher, significantly increasing cost.

Clinically, metformin ER is preferred by some prescribers for patients who experience gastrointestinal side effects (nausea, diarrhea, abdominal cramping) with IR formulations. A 2016 Cochrane review found that extended-release formulations reduced GI adverse events without meaningfully changing glycemic efficacy [12]. If your prescriber recommends ER specifically for tolerability and your plan places the brand product at a higher tier, requesting the generic ER formulation (often labeled "metformin hydrochloride ER") should preserve Tier 1 pricing.

One caveat: In 2020, the FDA issued a voluntary recall of several extended-release metformin products due to elevated N-nitrosodimethylamine (NDMA) levels [13]. Not all ER products were affected, and the recall did not extend to immediate-release metformin. Products that passed FDA testing remained on pharmacy shelves. As of early 2025, the FDA considers the metformin ER supply that has not been recalled to be safe for dispensing.

Metformin for Off-Label Uses: Will UHC Cover It?

Prescribers sometimes use metformin off-label for polycystic ovary syndrome (PCOS), prediabetes, gestational diabetes management, weight management, and investigational longevity purposes. UHC coverage for off-label use depends on whether the plan's medical policy considers the indication "medically necessary" and whether the diagnosis code submitted supports coverage.

For PCOS, UHC medical policy may require documentation of hyperinsulinemia or insulin resistance before approving metformin. Several UHC commercial plan policies reference ACOG Committee Opinion guidelines on PCOS as a basis for coverage decisions. ACOG acknowledges metformin as an option for PCOS-related metabolic abnormalities but notes that it is not FDA-approved for PCOS [14].

For prediabetes (ICD-10 code R73.09), some UHC plans cover metformin when the prescriber documents DPP enrollment failure or contraindications to lifestyle intervention, citing the DPP trial data (N=3,234) showing 31% reduction in diabetes progression [8]. Other UHC plans do not cover metformin for prediabetes without an explicit diabetes diagnosis code.

For purely longevity or anti-aging indications, UHC will not cover metformin. No FDA approval exists for those uses, and UHC's pharmacy benefit criteria require an FDA-approved or guideline-supported indication for formulary coverage.

Metformin and the Telehealth Prescribing Context

Telehealth platforms, including HealthRX, can evaluate patients for metformin prescriptions when a qualifying diagnosis exists. A provider licensed in your state completes a clinical assessment, confirms the indication (type 2 diabetes, PCOS with documented metabolic criteria, or prediabetes with appropriate documentation), and sends the prescription electronically to your preferred pharmacy.

When the prescription reaches your pharmacy, it processes through your UHC benefit exactly as any in-office prescription would. The prescriber's NPI number and DEA number (if applicable) are transmitted, and UHC adjudicates the claim in real time. Metformin is not a controlled substance, so no DEA number is required and telehealth prescribing restrictions that apply to controlled substances do not apply here.

Patients starting metformin through telehealth should know that the ADA recommends beginning at 500 mg once or twice daily with meals to minimize GI side effects, titrating by 500 mg per week as tolerated to a target dose of 1,500 to 2 to 000 mg per day in divided doses [2]. Maximum approved daily dose is 2 to 550 mg, though doses above 2 to 000 mg add limited additional glycemic benefit and increase GI burden.

Renal function must be assessed before starting metformin. The FDA updated its metformin contraindication guidance in 2016, changing the threshold from serum creatinine-based cutoffs to eGFR-based criteria. Metformin is now contraindicated when eGFR falls below 30 mL/min/1.73 m² and requires caution with eGFR between 30 and 45 mL/min/1.73 m² [13]. A basic metabolic panel ordered through the telehealth platform covers this requirement.

Practical Steps to Get Metformin Covered Under UHC

1. Confirm your diagnosis code with your prescriber. Type 2 diabetes (E11.9) or PCOS with metabolic features (E28.2 plus relevant metabolic code) are the most straightforward paths to coverage without PA.

2. Ask the prescriber to write "metformin hydrochloride" generically, not a brand name, on the prescription. This prevents automatic assignment to a higher tier.

3. Use a 90-day mail-order supply if your UHC plan offers it. Mail-order typically costs the same copay as a 30-day retail fill, providing 3 months of medication for the price of one copay.

4. If you are in a high-deductible period and the deductible makes even generic metformin expensive, present a GoodRx coupon at the pharmacy counter and pay cash. Many plans allow you to apply cash-pay prices toward your deductible if you request a receipt and submit it manually, though UHC's specific rules on this vary by plan document.

5. Check whether your employer's Health Savings Account (HSA) or Flexible Spending Account (FSA) covers the metformin copay. Both HSA and FSA funds can pay for prescription drugs, including metformin, tax-free.

The Endocrine Society's 2023 clinical practice guideline for type 2 diabetes states that "access to affordable first-line agents including metformin is a foundational element of equitable diabetes care" [15]. UHC's Tier 1 placement of generic metformin aligns with that principle for the vast majority of its members.